Abstract: The present invention discloses a patient-reported assessment tool dedicated for assessment of oxaliplatin-induced peripheral neuropathy (OIPN), comprising a main scale, a subscale and a scoring formula. The assessment contents of the main scale contain symptoms of body organs and are graded based on patient's subjective feelings about the frequency of the neuropathy, corresponding to relative scores. The assessment contents of the subscale contain location, duration and influence of the most severe symptom. The present invention effectively improves the accuracy and sensitivity of CIPN assessment through the targeted application range design and the maximum item weight addition, and improves the clinical reference value of CIPN assessment by elaborating the description of OIPN symptoms and integrating the features of several validated assessment tools, and provides reference for the development of CIPN assessment tools.

Abstract: The present invention discloses a pharmaceutical composition for treating cancer, comprising: (1) a herbal composition generated from Astragali membranaceus radix, Cinnamomi cortex, Paeonia alba radix, Jujubae fructus, and Zingiberis rhizoma or an extract of the above mixed herbal medicine; (2) one or more chemotherapeutic compounds. The present invention also discloses use of the above pharmaceutical composition in the preparation of medicament for treating human cancer and in the preparation of medicament for reducing side effects of chemotherapeutic compounds in human body. The pharmaceutical composition of the present invention can reduce chemotherapy-induced peripheral neuropathic side effects such as limb paresthesia, pain, cold skin, formication, powerlessness and the like, increase tolerance dosages of anticancer drugs, and enhance efficacy of anticancer drugs.